European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of pembrolizumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first combination of immunotherapy (pembrolizumab) with a tyrosine kinase inhibitor (axitinib) to receive a […]

read more
Showing the single result
  TOP